The care and feeding of a commercial liposomal product: liposomal amphotericin B (AmBisome^®)

References

• Adler-Moore, J.P. and Proffitt, R.T., 1993. Development, characterization, efficacy and mode of action of Ambisome, a unilamellar liposomal formulation of amphotericin B. Journal of liposome research, 3, 429–450.
   Google Scholar
• Adler-Moore, J., Jensen, G. M., and Proffitt, R., 2006. Liposomal therapeutics: from animal to man. In: G. Gregoriadis, ed. Liposome technology. 3rd ed. Boca Raton, FL: CRC Press, Volume 3, 405–416.
   Google Scholar
• Adler-Moore, J.P., Gangneux, J.P., and Pappas, P.G., 2016. Comparison between liposomal formulations of amphotericin B. Medical mycology, 54, 223–231.
   PubMed Web of Science ®Google Scholar
• Adler-Moore, J.P., et al., 2017. Tissue pharmacokinetics and pharmacodynamics of Ambisome (L-AmBis) in uninfected and infected animals and their effects on dosing regimens. Journal of liposome research. doi:10.1080/08982104.2017.1327543
   Web of Science ®Google Scholar
• Cornely, O.A., et al., 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clinical infectious disease, 44, 1289–1297.
   PubMed Web of Science ®Google Scholar
• Cornely, O.A., et al., 2017. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. Journal of antimicrobial chemotherapy, 72, 2359–2367.
   PubMed Web of Science ®Google Scholar
• Garey, K.W., et al., 2001. Cunninghamella bertholletiae infection in a bone marrow transplant patient: amphotericin lung penetration, MIC determinations, and review of the literature. Pharmacotherapy, 21 (7), 855–860.
   PubMed Web of Science ®Google Scholar
• Jensen, G.M., et al., 1999. Determination of the relative toxicity of amphotericin B formulations: a red blood cell potassium release assay. Drug Delivery, 6, 81–88.
   Web of Science ®Google Scholar
• Jensen, G. M., et al., 2006. Process development and quality control of injectable liposome therapeutics, In: G. Gregoriadis, ed. Liposome technology. 3rd ed. Boca Raton, FL: CRC Press, Volume 1, 297–310.
   Google Scholar
• Jensen, G.M., et al., 2008. A liposomal dispersion formulation of propofol: formulation, pharmacokinetics, stability, and identification of an oxidative degradant. Theoretical chemistry accounts, 119 (1–3), 291–296.
   Web of Science ®Google Scholar
• Jensen, G.M., and Bunch, T., 2007. Conventional liposome performance and evaluation: lessons from the development of vescan. Journal of liposome research, 17, 121–137.
   PubMed Web of Science ®Google Scholar
• Jensen, G.M., et al., 2010. Erroneous determination of hyperphosphatemia (‘Pseudohyperphosphatemia’) in sera of patients that have been treated with liposomal amphotericin B (AmBisome). Clinica chimica acta, 411, 1900–1905.
   PubMed Web of Science ®Google Scholar
• Jensen, G. M., and Soo Hoo, L., 2014. Regulatory aspects of pharmaceutical nanopreparations. In: V.. Torchilin, ed. Frontiers of nanobiomedical research – A WSPC reference on the state-of-the-art: fundamentals, main applications, and vision for the future. Singapore: World Scientific, 119–143.
   Google Scholar
• Lestner, J.M. et al., 2010. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrobial agents chemotherapy, 54, 3432–3441.
   PubMed Web of Science ®Google Scholar
• Olson, J.A., et al., 2006. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrobial agents chemotherapy, 50, 2122–2131.
   PubMed Web of Science ®Google Scholar
• Olson, J.A., et al., 2008. Comparision of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrobial agents chemotherapy, 52, 259–268.
   PubMed Web of Science ®Google Scholar
• Olson, J.A., et al., 2015. Toxicity and efficacy differences between liposomal Amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice. Medical mycology, 53 (2), 107–118.
   PubMed Web of Science ®Google Scholar
• Prentice, H.G., et al., 1997. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. British journal of haematology, 98, 711–718.
   PubMed Web of Science ®Google Scholar
• Ritter, J.M., Exserohilum Infections Working Group., et al., 2013. Exserohilum infections associated with contaminated steroid injections: a clinicopathologic review of 40 cases. American journal of pathology, 183 (3), 881–892.
   PubMed Web of Science ®Google Scholar
• Stone, N.R.H., et al., 2016. Liposomal amphotericin B (AmBisome): a review of pharmacokinetics, pharmacodynamics, clinical experience, and future directions. Drugs, 76 (4), 485–500.
   PubMed Web of Science ®Google Scholar
• Sundar, S., et al., 2010. Single-dose liposomal amphotericin b for visceral leishmaniasis in India. The new England journal of medicine, 362, 504–512.
   PubMed Web of Science ®Google Scholar
• Walsh, T.J., et al., 1999. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. new England journal of medicine, 340, 764–771.
   PubMed Web of Science ®Google Scholar
• Wingard, J.R., et al., 2000. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clinical infectious diseases: an official publication of the infectious diseases society of America, 31, 1155–1163.
   PubMed Web of Science ®Google Scholar